Table 2. Prescribed medical therapies at baseline based on age, sex and left ventricular ejection fraction.

	All				LVEF ≤40%				LVEF >40%
	Men (n=591)	Women (n=290)	P		Men (n=322)	Women (n=132)	P		Men (n=269)	Women (n=158)	P
Beta-blocker	433 (73.4)	209 (72.1)	0.69		266 (82.6)	100 (75.8)	0.12		167 (62.1)	109 (69.0)	0.17
ACE inhibitor	433 (73.3)	198 (68.3)	0.13		254 (78.9)	94 (71.2)	0.09		179 (66.5)	104 (65.8)	0.92
ARB	109 (18.5)	71 (24.5)	0.041		59 (18.3)	33 (25.0)	0.12		50 (18.6)	38 (24.1)	0.22
MRA	195 (33.0)	108 (37.4)	0.2		147 (45.7)	68 (51.5)	0.26		48 (36.4)	40 (25.3)	0.08
Loop diuretic	262 (44.3)	125 (43.1)	0.77		201 (62.4)	90 (68.2)	0.28		61 (22.7)	35 (22.2)	1.0

	All				LVEF ≤40%				LVEF >40%
	<60 (n=597)	≥60 (n=284)	P		<60 (n=295)	≥60 (n=159)	P		<60 (n=302)	≥60 (n=125)	P
Beta-blocker	435 (72.9)	207 (73.1)	1.0		246 (83.4)	120 (75.5)	0.05		189 (62.6)	87 (69.6)	0.18
ACE inhibitor	429 (71.9)	202 (71.1)	0.87		225 (76.3)	123 (77.4)	0.82		204 (67.5)	79 (63.2)	0.43
ARB	113 (19.0)	67 (23.7)	0.11		63 (21.4)	29 (18.2)	0.46		50 (16.6)	38 (30.4)	0.002
MRA	208 (34.9)	95 (33.5)	0.7		153 (51.9)	62 (39.0)	0.01		55 (18.2)	33 (26.4)	0.07
Loop diuretic	233 (39.0)	154 (54.2)	<0.0001		182 (61.7)	109 (68.6)	0.15		51 (16.9)	45 (36.0)	0.0001

(ACE – angiotensin converting enzyme, ARB – angiotensin II receptor blocker, MRA – mineralocorticoid antagonist)